Global Autologous Cell Therapy Market By Source (Bone Marrow, Epidermis, Mesenchymal Stem Cells, Hematopoietic Stem Cells, and Chondrocytes), By Application (Cancer, Neurodegenerative Disorders, Cardiovascular Disorders, Autoimmune Disorders, Orthopedics, and Wound Healing), By End-User (Hospitals & Clinics, Ambulatory Centers, and Academics & Research), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032
- Published date: Oct 2023
- Report ID: 99956
- Number of Pages: 341
- Format:
-
keyboard_arrow_up
-
-
- BrainStorm Cell Therapeutics
- Holostem Terapie Avanzate S.R.L
- Pharmicell Co. Inc
- Opexa Therapeutics
- Caladrius Biosciences Inc.
- S. Stem Cell Inc.
- Lonza Group AG Company Profile
- Bristol Myers Squibb Company Profile
- Novartis AG Company Profile
- Autolus therapeutics
- Tego Science
- Corning Inc.
- Bio Elpida
- Vericel Corporation
- Catalent Inc.
- Sartorius AG
- Other Key Players
- settingsSettings
Our Clients
- 99956
- Oct 2023
Trusted by more than 17382 organizations globally
✖
Request a Sample Report
We'll get back to you as quickly as possible
|
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
|---|---|---|---|
| e-Access | |||
| Report Library Access | |||
| Data Set (Excel) | |||
| Company Profile Library Access | |||
| Interactive Dashboard | |||
| Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
| Accessibility | 1 User | 2-5 User | Unlimited |
| Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
| Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
| Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |
